New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
08:13 EDTOHRPOhr Pharmaceutical announces initiation of Phase II trial for OHR-005
Ohr Pharmaceutical announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing Squalamine Eye Drops in patients with diabetic macular edema. OHR-005 is a randomized, placebo controlled, investigator sponsored, multicenter Phase II clinical trial evaluating the effect of Squalamine Eye Drops in patients with DME. The primary endpoints will measure change in retinal thickness and change in Best Corrected Visual Acuity over 24 weeks. Secondary objectives include additional BCVA measurements, change in foveal thickness, evaluation of the need for rescue injections of ranibizumab and an assessment of the safety and tolerability of Squalamine Eye Drops.
News For OHRP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
10:20 EDTOHRPOhr Pharmaceutical price target lowered to $15 from $25 at Cowen
Subscribe for More Information
10:01 EDTOHRPHigh option volume stocks
Subscribe for More Information
09:30 EDTOHRPOhr Pharmaceutical downgraded to Neutral from Buy at Chardan
Price target $8.
09:26 EDTOHRPOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTOHRPOhr Pharmaceutical data better than may seem, says Brean Capital
Subscribe for More Information
07:49 EDTOHRPOhr Pharmaceutical to host conference call
Subscribe for More Information
07:14 EDTOHRPOhr Pharmaceutical announces final topline data from OHR-102 Phase II study
Ohr Pharmaceutical announced the topline results from the exploratory Phase II IMPACT study evaluating OHR-102 combination therapy for the treatment of the wet form of age-related macular degeneration, or wet-AMD. In the intent-to-treat, or ITT-LOCF population with classic containing choroidal neovascularization, or CNV, 42% of the patients receiving OHR-102 achieved a 3 line gain at nine months, as compared to 28% in the Lucentis monotherapy group. Less of a benefit was seen in the overall population. The classic containing CNV population represents approximately two thirds of the total wet-AMD population. The positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to increase through the end of the study, supporting the planned Phase III development program. In patients with classic CNV, mean gains in visual acuity were +10.5 letters for the OHR-102 combination arm and +5.4 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.1 letters. The mean number of injections between the treatment arms, the primary endpoint of the study, was not meaningfully different.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use